When people seek help at a drug treatment center for an opioid addiction, concerns about having contracted hepatitis C are generally low on their list.
Nearly 100,000 people are waiting for a kidney transplant in the U.S., but many will never get one. Instead they’ll stay on dialysis for the rest of their lives. A team of doctors in Philadelphia have found a possible solution to this problem.
Two new pangenotypic drug combinations are awaiting approval for hepatitis C in Europe, and could also receive approval in the U.S. by the end of the year.